Phase I/II Trial to Evaluate Safety, Tolerability and Pharmacokinetic Profile of HM61713 in NSCLC Patients
The main objective of this study is to evaluate the safety and tolerability of HM61713.
Non Small Cell Lung Cancer
DRUG: HM61713
Safety and tolerability, Dose limiting Toxicity will be evaluated on Day 24 during Cycle 1
Besides the main objective, there are 3 other objectives as follows:

* To evaluate the anti-cancer effect of HM61713 in NSCLC patients with EGFR mutation
* To investigate the pharmacokinetic profile of HM61713 and its metabolites after oral administration
* To investigate biomarkers related to the safety and efficacy of HM61713